Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells

Journal of Nutritional Biochemistry

Volumn 20, Issue 4, 2009, Pages 261-268

  Siripurkpong, Pilaiwan ^a   Na Bangchang, Kesara ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Apolipoprotein A 1; ATP binding cassette transporter A1; Chromium; Niacin

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CHROMIUM; CHROMIUM CHLORIDE; HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ABCA1 GENE; APOA GENE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DIET; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CHROMIUM; HUMANS; LIPID METABOLISM; NIACIN; PPAR ALPHA; RNA, MESSENGER; TRACE ELEMENTS; TRANSCRIPTION, GENETIC;

EID: 61849102939     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2008.02.010     Document Type: Article

References (60)

1. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., and Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study. JAMA 256 (1986) 2835-2838
2. Castelli W.P., Anderson K., Wilson P.W., and Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 2 (1992) 23-28
3. Gordon D.J., and Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
4. Kannel W. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 52 (1983) 9B-12B
5. Rader DJ. Protective effects of HDL-C and need to raise low levels explored. Am J Manag Care 2002;Suppl:2, 4.
6. Wang M., and Briggs M.R. HDL: the metabolism, function, and therapeutic importance. Chem Rev 104 (2004) 119-137
7. Brewer Jr. H.B., Remaley A.T., Neufeld E.B., Basso F., and Joyce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 24 (2004) 1755-1760
8. Fielding C.J., and Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res 36 (1995) 211-228
9. Sampietro T., Bigazzi F., Pino B.D., Puntoni M., and Bionda A. HDL: The 'new' target of cardiovascular medicine. Int J Cardiol 108 (2006) 143-154
10. Assmann G., and Gotto Jr. A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 109 (2004) III8-III14
11. Jialal I., and Devaraj S. The role of oxidized low density lipoprotein in atherogenesis. J Nutr 126 (1996) 1053S-1057S
12. Navab M., Imes S.S., Hama S.Y., Hough G.P., Ross L.A., Bork R.W., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88 (1991) 2039-2046
13. Pisciotta L., Hamilton-Craig I., Tarugi P., Bellocchio A., Fasano T., Alessandrini P., et al. Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. Atherosclerosis 172 (2004) 309-320
14. Hovingh G.K., Kuivenhoven J.A., Bisoendial R.J., Groen A.K., van Dam M., van Tol A., et al. HDL deficiency and atherosclerosis: lessons from Tangier disease. J Intern Med 255 (2004) 299-301
15. Rogler G., Trumbach B., Klima B., Lackner K.J., and Schmitz G. HDL-mediated efflux of intracellular cholesterol is impaired in fibroblasts from Tangier disease patients. Atherioscler Thromb Vasc Biol 15 (1995) 683-690
16. Oram J.F. Tangier disease and ABCA1. Biochim Biophys Acta 1529 (2000) 321-330
17. Sahoo D., Trischuk T.C., Chan T., Drover V.A., Ho S., Chimini G., et al. ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes. J Lipid Res 45 (2004) 1122-1131
18. Glomset J.A., Janssen E.T., Kennedy R., and Dobbins J. Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res 7 (1966) 638-648
19. Langmann T., Porsch-Ozcurumez M., Heimerl S., Probst M., Moehle C., Taher M., et al. Identification of sterol-independent regulatory elements in the human ATP-binding cassette transporter A1 promoter: role of Sp1/3, E-box binding factors, and an oncostatin M-responsive element. J Biol Chem 277 (2002) 14443-14450
20. Yang X.P., Freeman L.A., Knapper C.L., Amar M.J., Remaley A., Brewer Jr. H.B., et al. The E-box motif in the proximal ABCA1 promoter mediates transcriptional repression of the ABCA1 gene. J Lipid Res 43 (2002) 297-306
21. Ruan X.Z., Moorhead J.F., Fernando R., Wheeler D.C., Powis S.H., and Varghese Z. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 14 (2003) 593-600
22. Basso F., Freeman L., Knapper C.L., Remaley A., Stonik J., Neufeld E.B., et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res 44 (2003) 296-302
23. Tall A.R. Role of ABCA1 in cellular cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 23 (2003) 710-711
24. Wang N., Silver D.L., Thiele C., and Tall A.R. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 276 (2001) 23742-23747
25. Tavintharan S., and Kashyap M.L. The benefits of niacin in atherosclerosis. Curr Atheroscler Rep 3 (2001) 74-82
26. Sakai T., Kamanna V.S., and Kashyap M.L. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. [see comment]. Arterioscler Thromb Vasc Biol 21 (2001) 1783-1789
27. Kamanna V.S., and Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2 (2000) 36-46
28. Ganji S.H., Kamanna V.S., and Kashyap M.L. Niacin and cholesterol: role in cardiovascular disease. [Review]. J Nutr Biochem 14 (2003) 298-305
29. Ganji S.H., Tavintharan S., and Zhu D. Niacin non-competitively inhibits hepatocyte diacylglycerol acyltransferase, a key enzyme for triglyceride synthesis. Arterioscler Thromb Vasc Biol 22 (2002) 878 [Abtract]
30. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin decrease removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 17 (1997) 2020-2028
31. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 19 (1999) 1051-1059
32. Mossop R.T. Effects of chromium III on fasting blood glucose, cholesterol and cholesterol HDL levels in diabetics. Cent Afr J Med 29 (1983) 80-82
33. Mertz W. Chromium in human nutrition: a review. J Nutr 123 (1993) 626-633
34. Riales R., and Albrink M.J. Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. Am J Clin Nutr 34 (1981) 2670-2678
35. Schroeder H.A., Nason A.P., and Tipton I.H. Chromium deficiency as a factor in atherosclerosis. J Chronic Dis 23 (1970) 123-142
36. Roeback Jr. J.R., Hla K.M., Chambless L.E., and Fletcher R.H. Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers. A randomized, controlled trial. Ann Intern Med 115 (1991) 917-924
37. Abraham A.S., Brooks B.A., and Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism 41 (1992) 768-771
38. Haas M.J., Sawaf R., Horani M.H., Gobal F., Wong N.C., and Mooradian A.D. Effect of chromium on apolipoprotein A-I expression in HepG2 cells. Nutrition 19 (2003) 353-357
39. Rubic T., Trottmann M., and Lorenz R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67 (2004) 411-419
40. Kielar D., Dietmaier W., Langmann T., Aslanidis C., Probst M., Naruszewicz M., et al. Rapid quantification of human ABCA1 mRNA in various cell types and tissues by real-time reverse transcription-PCR. Clin Chem 47 (2001) 2089-2097
41. Major A.S., Dove D.E., Ishiguro H., Su Y.R., Brown A.M., Liu L., et al. Increased cholesterol efflux in apolipoprotein AI (ApoAI)-producing macrophages as a mechanism for reduced atherosclerosis in ApoAI[(-/-)] mice. Arterioscler Thromb Vasc Biol 21 (2001) 1790-1795
42. Tachibana K., Kobayashi Y., Tanaka T., Tagami M., Sugiyama A., Katayama T., et al. Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nucl Recept 3 (2005) 3
43. Cheung I.Y., and Cheung N.K. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 7 (2001) 1698-1705
44. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29 (2001) 2005-2007
45. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 (1959) 911-917
46. Porsch-Ozcurumez M., Langmann T., Heimerl S., Borsukova H., Kaminski W.E., Drobnik W., et al. The zinc finger protein 202 (ZNF202) is a transcriptional repressor of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene expression and a modulator of cellular lipid efflux. J Biol Chem 276 (2001) 12427-12433
47. Shepherd J., Packard C.J., and Patsch J.R. Effect of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 63 (1979) 858-867
48. Sakai T., Kamanna V.S., and Kashyap M.L. Niacin but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 21 (2001) 1783-1789
49. Zhang Y., Beyer T.P., Bramlett K.S., Yao S., Burris T.P., Schmidt R.J., et al. Liver X receptor and retinoic X receptor mediated ABCA1 regulation and cholesterol efflux in macrophage cells-messenger RNA measured by branched DNA technology. Mol Genet Metab 77 (2002) 150-158
50. Schwartz K., Lawn R.M., and Wade D.P. ABC1 gene expression and Apo A-I mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun 275 (2000) 794-802
51. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 (2001) 161-171
52. Aguilar M.V., Martinez-Para M.C., and Gonzalez M.J. Effects of arsenic (V)-chromium (III) interaction on plasma glucose and cholesterol levels in growing rats. Ann Nutr Metab 41 (1997) 189-195
53. Press R.I., Geller J., and Evans G.W. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. West J Med 152 (1990) 41-45
54. Harnish D.C., Evans M.J., Scicchitano M.S., Bhat R.A., and Karathanasis S.K. Estrogen regulation of the apolipoprotein AI gene promoter through transcription cofactor sharing. J Biol Chem 273 (1998) 9270-9278
55. Mooradian A.D., Haas M.J., and Wong N.C. The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr Rev 27 (2006) 2-16
56. Curran G.L. Effect of certain transition group elements on hepatic synthesis of cholesterol in the rat. J Biol Chem 210 (1954) 765-770
57. National Research Council. Recommended Dietary Allowances (1989), National Academy Press, Washington (DC) 284
58. Doisy R.J., Streeten D.H.P., and Freiberg J.M. Chromium metabolism in man and biochemical effects. In: Prasad A.S. (Ed). Trace Elements in Human Health and Disease (1976), Academy Press, New York
59. Lefavi R.G., Anderson R.A., Keith R.E., Wilson G.D., McMillan J.L., and Stone M.H. Efficacy of chromium supplementation in athletes: emphasis on anabolism. Int J Sport Nutr 2 (1992) 111-122
60. Thomas V.L., and Gropper S.S. Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors. Biol Trace Elem Res 55 (1996) 297-305